Phage and yeast display has yielded a staggering arsenal of multispecific antibodies, antibody-drug conjugates, immunotherapies, and numerous other constructs. The emergence of computational tools are being applied to improve selection, design, and efficacy of candidates and predictive measures of success in the translation to effective drug candidates. Newer, sophisticated methods of conditional activation approaches will allow biologics to hit the tumour before they become activated, reducing off-target toxicity and adverse events. The 11th Annual Display of Biologics conference is the cornerstone of the PEGS Europe Summit, and will highlight progress and approaches leading to new classes of therapy.
Scientific Advisory Board:
Joao Goncalves, PhD, Full Professor, Microbiology & Immunology, University of Lisbon
Ahuva Nissim, PhD, Professor, Antibody and Therapeutic Engineering, William Harvey Research Institute, Queen Mary University of London
E. Sally Ward, PhD, Director, Translational Immunology; Professor, Molecular Immunology, Centre for Cancer Immunology, University of Southampton